|FOX40WDBD.COM||Look for the ridiculous in everything!|
|Student Loans | | Phone Services | High Speed Internet Service | World Cruises | | Save Money|
Michael Kors Hamilton Canvas Tote
New York Based Dipexium Pharmaceuticals (DPRX) Prices Upsized IPO At $12, Raises $33 Million Concert Pharmaceuticals, Inc. (CNCE) Heads To Nasdaq, Prices At High End Of The Range
Galmed Pharmaceuticals Announces Pricing of Initial Public Offering
can be obtained from: Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, (800) 724 0761; MLV Co, LLC, Attention: Randy Billhardt, 1251 Avenue of the Americas, 41st Floor, New York, NY 10020, (212) 542 5882; and Feltl and Company, Inc., Prospectus Department, 800 LaSalle Avenue, Suite 2100, Minneapolis, MN 55402, (612) 492 8800.
Allen Baharaff, CEO+972 (3) 693 8448
This press release shall not constitute an offer to sell or the solicitation of Michael Kors Handbags On Sale
Small Biotech Recro Pharma (REPH) Secures A $30 Million IPO Feat Beijing Genomics Institute (BGI) Rumored To Stage $400 Million IPO In Late 2014
Galmed is a clinical stage biopharmaceutical company focused on the development and commercialization of a novel, once daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first in class family of synthetic fatty acid/bile acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non Alcoholic Steato Hepatitis, or NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
Cautionary Note on Forward Looking Statements
any forward looking statements.
This press release includes forward looking statements, including statements relating to the anticipated closing of the initial public offering. Such forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the prospectus related to the initial public offering, and in other filings that Galmed may make with the SEC in the future. The forward looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update Michael Kors Shoulder Bag Uk
Galmed Pharmaceuticals Debuts Upsized IPO Raises 38 Million
an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Galmed Pharmaceuticals Ltd.
Help employers find you! Check out all the .
TEL AVIV, Israel, March 12, 2014 /PRNewswire/ Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 Michael Kors Hamilton Canvas Tote per share, before underwriting discounts and commissions. The shares to be issued in the offering have been approved for listing on the NASDAQ Capital Market and are expected to begin trading under the ticker symbol "GLMD" on March 13, 2014. Securities and Exchange Commission on March 12, 2014. The offering is being made only by means of a prospectus, copies of which Michael Kors Hamilton Crossbody Handbag
Michael Kors Hamilton Canvas Tote
Michael Kors Black Bag Tumblr
|Gift Baskets | | Long Distance Rates | Credit Reporting | Wireless | | Online Stores|